Gilead (GILD) Announced Interim Phase 2 Data on Hepatitis Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Gilead Sciences (NASDAQ: GILD) | Delayed: 156.04 -1.15 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.19 | 52 Week High | $108.63 | |||
| Open | $156.47 | 52 Week Low | $71.39 | |||
| Day High | $157.65 | P/E | 86.21 | |||
| Day Low | $155.76 | EPS | $1.81 | |||
| Volume | 6,070,932 | |||||
